Table 3. Univariate and multivariate analyses for survival and recurrence in cohort 1.
Factors | Overall survival | Recurrence-free survival | ||||||
---|---|---|---|---|---|---|---|---|
Univariate P | Multivariate | Univariate P | Multivariate | |||||
HR | 95% CI | P | HR | 95% CI | P | |||
Age: ≤ 50 vs > 50 years | .150 | NA | .604 | NA | ||||
Gender: female vs male | .430 | NA | .320 | NA | ||||
Hepatitis B history: no vs yes | .219 | NA | .915 | NA | ||||
HBeAg: negative vs positive | .106 | NA | .004 | 1.554 | 1.092–2.212 | .014 | ||
Liver cirrhosis: no vs yes | .076 | NA | .151 | NA | ||||
ALT: ≤ 75 vs > 75 U/L | .716 | NA | .391 | NA | ||||
AFP: ≤ 300 vs > 300 ng/dl | .088 | NA | .055 | NA | ||||
Tumor size: ≤ 5 vs > 5 cm | < .001 | 2.565 | 1.666–3.948 | < .001 | < .001 | 1.469 | 1.013–2.129 | .042 |
Tumor differentiation: low vs high | .001 | 1.706 | 1.134–2.566 | .010 | .010 | NS | ||
Tumor number: single vs multiple | .013 | NS | .001 | NS | ||||
Intrahepatic metastasis: no vs yes | < .001 | 1.804 | 1.137–2.861 | .012 | < .001 | 2.055 | 1.306–3.232 | .002 |
Tumor encapsulation: no vs complete | .098 | NA | .288 | NA | ||||
Microvascular invasion: no vs yes | < .001 | NS | < .001 | NS | ||||
TNM stage: I vs II vs IIIA | < .001 | 1.663 | 1.128–2.453 | .010 | < .001 | 1.724 | 1.262–2.355 | .001 |
HTATIP2 density: low vs high | < .001 | 0.841 | 0.380–0.986 | .001 | < .001 | 0.676 | 0.367–0.881 | .039 |
Microvessel density: low vs high | < .001 | 4.084 | 2.560–6.514 | < .001 | < .001 | 2.361 | 1.621–3.439 | < .001 |
Combine HTATIP2 and microvessel density | < .001 | NA | < .001 | NA |
Abbreviations: HR, hazard ratio; CI, confidence interval; NA, not adopted; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AFP, α-fetoprotein; NS, not significant; TNM, tumor-node-metastasis; HTATIP2, HIV-1 Tat interactive protein 2.